AMD Home Monitoring Device Reaches Landmark Milestone
CHANTILLY, Va.–(BUSINESS WIRE)–October 20, 2014–
Notal Vision, Inc. recently recorded its one-millionth individual test on its ForeseeHome® AMD Monitoring System. The ForeseeHome AMD Monitoring System is the first technological advancement in the monitoring for early changes in Age-related Macular Degeneration (AMD) that may be associated with the conversion of dry AMD to the wet form of AMD.
“The recording of the one-millionth test is a significant milestone for our company as the ForeseeHome System demonstrates a technical sophistication to perform and capture meaningful data with respect to disease progression in AMD,” Notal Vision CEO, Dr. Barak Azmon states. “We are pleased with the support Notal Vision has received from both the Retina and greater ophthalmic communities. Our commitment to patients continues to be a proven system for monitoring AMD through at-home testing with ForeseeHome.”
About ForeseeHome™ AMD Monitoring Program
The ForeseeHome AMD Monitoring Program is a prescription-based, comprehensive telemonitoring and data management system that extends the management of AMD to patients’ homes between office visits. The test results are transmitted to a central monitoring center that will alert, physicians to immediate, significant visual field changes in their patients, so that patients can be recalled for timely follow-up and necessary treatment may be initiated. The ForeseeHome AMD Monitoring Program utilizes a simple to use device based on preferential hyperacuity perimetry, a form of visual-field testing, to identify minute visual distortions, or metamorphopsia, for the detection of early CNV development.
About Notal Vision™
Notal Vision was founded by two ophthalmologists, and is committed to providing retina specialists with innovative, home-based, technology solutions that support visual health in patients with AMD. The company’s ForeseeHome device is the first FDA-cleared home tele-monitoring device that detects and characterizes visual distortion in AMD patients as an aid to monitoring progression to CNV.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more